Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -208.99 M

Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure is USD -208.99 M for the year ending December 31, 2023, a 27.61% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -288.69 M, a -10.19% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -261.98 M, a -208.49% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -84.92 M, a -5.35% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -80.61 M, a -4.78% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years